ArticleACS omega2026
Photopolymerizable Imidazolium Methacrylate Networks for Controlled Dexamethasone Release: Potential Application in Uveitis Therapy.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study focuses on the development of photopolymerizable systems using imidazolium methacrylate, a liquid salt made from imidazole and methacrylic acid, cross-linked with either cyclohexanedimethanol dimethacrylate (CDMM) or ethylene glycol dimethacrylate (EGDMA). These systems are specifically designed for the controlled release of dexamethasone in ocular applications. The swelling behavior, mechanical characteristics, drug release kinetics, and biocompatibility of the resulting materials on different cell lines were evaluated. The dexamethasone release process was governed by a combination of diffusion and polymer matrix relaxation, influenced by drug-polymer interactions and temperature. Implants containing higher dexamethasone concentrations exhibited a release mechanism predominantly controlled by polymer relaxation, associated with chain reorganization. The results revealed that the release profiles varied with the cross-linking agent used and showed significant temperature dependence. At average body temperature, increased matrix swelling and faster release rates were observed. It was observed that higher drug concentrations led to greater porosity, thereby promoting faster release. Conversely, cross-linking agents with lower steric hindrance produced denser networks, resulting in reduced release rates. All tested formulations showed good cytocompatibility. These findings highlight the potential of imidazolium methacrylate-based photopolymerizable systems for applications in personalized medical devices, particularly for controlled and/or localized corticosteroid delivery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.